The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.

This invention provides methods and compositions for preventing, treating or ameliorating one or more symptoms of a malignant tumor associated with KRAS mutation in a mammal in need thereof, by identifying a tumor cell in the mammal, the tumor cell comprising at least one of: (i) a mutation of the KRAS gene, and (ii) an aberrant expression level of KRAS protein; and administering to the mammal a therapeutically effective amount of a composition comprising one or more RNAi molecules that are active in reducing expression of GST-π.

A fluorescent solution is disclosed for use in a hydraulic or diesel fluid to facilitate detection of injection of the hydraulic of diesel fluid into a human. The fluorescent solution includes a fluorescent dye and a stabilizing agent. The stabilizing agent may be a surfactant. A hydraulic fluid mixture is also disclosed which includes a fluorescent solution and a hydraulic fluid.

The present invention describes a receptor-targeting conjugate comprising a fluorophore; a molecule, e.g. a peptide, binding to the receptor; and —a linker group which covalently links the fluorophore to the molecule binding to the receptor, wherein the conjugate is adapted to be administered intravenously into a human or animal body, and provide an effective pharmacokinetic profile with reference to inter alia receptor binding affinity and removal from plasma.

The control unit includes, as a mechanical configuration, an image processing unit and a recording control unit. The image processing unit includes a combining unit that combines the fluorescence image acquired by the illuminating/photographing unit and the visible light image, a condition designation unit that designates an analysis condition and the like of an image analysis by an analyzing unit to be described later, and an analyzing unit that performs an analysis under the analysis condition designated by the condition designation unit. The storage unit includes an image storage unit including a reproduction moving image storage unit that stores a combined moving image obtained by combining the fluorescence image and the visible light image by the combining unit in the image processing unit as an irreversibly-compressed moving image file and an analysis moving image storage unit that stores a fluorescence moving image and a visible light moving image.

The bioluminescent system components are commonly used reagents for a variety of analyzes, including diagnostic systems, quality control systems, drug testing systems, etc. This group of inventions discloses the components of the bioluminescent system Odontosyllis undecimdonta worm, specifically luciferin and pre-luciferin. Besides, this group of inventions discloses a method for detecting luciferase in biological samples using luciferin and pre-luciferin of Odontosyllis undecimdonta worm, and also a method for detecting bioluminescence in a biological sample.

Provided herein is a drug delivery (DD) system for ratiometric luminescence determination of drug release degree in drug delivery monitoring, which includes a drug, a switchable reporter and non-switchable reporter providing two distinguishable signals for detection; or a single switchable reporter providing two distinguishable signals for detection, and a cleavable linker connecting a drug to a switchable reporter, as well as a method for ratiometric luminescence determination of drug release in a target (in vivo or in vitro), which is effected by administering the DD system provided herein that is capable of releasing a drug from the DD system, measuring two luminescent signals provided by the switchable reporter and the non-switchable reporter, or the single switchable reporter, determining the ratio between these two luminescence signals, and determining the drug release degree through the ratio between the two luminescence signals.

Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound.

##STR00001##

X represents CR.sup.7 or N.

R.sup.1 to R.sup.7, Q.sup.1, and Q.sup.2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by Formula (A), and adjacent substituents may form a ring structure.

However, at least one of R.sup.3, R.sup.4, R.sup.7, Q.sup.1, or Q.sup.2 contains, as a hydrophilic group, at least one of a carboxy group or a salt thereof, a sulfo group or a salt thereof, a phosphono group or a salt thereof, an onio group, or a polyamino acid residue, where at least one of Q.sup.1 or Q.sup.2 represents an alkyl group.

A molecular probe for labeling myelin includes a fluorescent trans-stilbene derivative.

Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.